<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00619905</url>
  </required_header>
  <id_info>
    <org_study_id>CACZ885A2101</org_study_id>
    <nct_id>NCT00619905</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Rheumatoid Arthritis With Ongoing Treatment With Methotrexate</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Cohort Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 (Anti-Interleukin-1Beta Monoclonal Antibody) in Patients With Active Rheumatoid Arthritis (RA) Despite Ongoing Treatment With Methotrexate (MTX) 15 mg or More Weekly for at Least 3 Months.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assessed the long-term safety and tolerability of ACZ885 in patients with
      rheumatoid arthritis, as well as long-term efficacy, long-term preservation and/or
      improvement of joint structure and bone mineral density, and long term maintenance of
      health-related quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">August 2005</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events and infections occurrence throughout the study.</measure>
    <time_frame>throughout the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of anti-ACZ885 antibodies in serum at baseline, Days 43, 71 and end of study (Day 113).</measure>
    <time_frame>throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACR response criteria [including joint counts, patient/investigator disease activity and pain assessment, acute phase reactants (ESR and CRP) and a Health Assessment Questionnaire (HAQ)] .</measure>
    <time_frame>throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score (DAS) at baseline and Days 43 and 113.</measure>
    <time_frame>throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of IL-1B, IL-6, and C-reactive protein (CRP), matrix metalloproteinases (MMPs) 1 and 3, and c-telopeptide of Type I collagen (Crosslaps), at Week 7 versus baseline.</measure>
    <time_frame>throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of ACZ885 at each visit.</measure>
    <time_frame>throughout the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACZ885</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACZ885</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients aged 18.5 - 65/75 years (depending on the dose group).

          -  Diagnosis of rheumatoid arthritis (ACR 1987 revised classification for criteria for
             RA) with a disease duration of at least 6 months prior to randomization.

          -  Active disease at screening and baseline evaluation (same evaluator) ) with more than
             6 tender and 6 swollen joints of 28 examined (including any effused joint) and either
             a) Westergren erythrocyte sedimentation (ESR) ≥ 28 mm/hour, or b) CRP ≥ 6 mg/L.

          -  Patients should have failed at least 1 DMARD in the past, but should not be deemed
             &quot;refractory to all therapies&quot;

          -  Patients should have a current treatment regimen of ≥ 15 mg methotrexate/week and with
             the current dose stable for approximately 3 months.

          -  Patients were required to have an otherwise stable RA therapeutic regimen, consisting
             of either a stable dose of NSAIDs and/or a stable dose of oral corticosteroids
             (prednisone or equivalent &lt; 10 mg daily) for at least 4 weeks prior to randomization.

        Exclusion Criteria:

          -  Previous treatment with anti-TNF-α antibody therapy (or other biological therapy)
             within appropriate timeframe (considering the half life of the compound)

          -  Patients who have received intra-articular or systemic corticosteroid injections
             having been required for treatment of acute RA flare (not being part of a regular
             therapeutic regimen) within four weeks prior to randomization OR require narcotic
             analgesics other than those accepted by the investigator for analgesia (e.g., codeine,
             tramadol, dextropropoxyphene)

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis investigator site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Koeln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Ratingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2008</study_first_submitted>
  <study_first_submitted_qc>February 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2008</study_first_posted>
  <last_update_submitted>February 8, 2008</last_update_submitted>
  <last_update_submitted_qc>February 8, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2008</last_update_posted>
  <responsible_party>
    <name_title>Novartis</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Anti-interleukin-1 beta</keyword>
  <keyword>ACZ885</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

